---

Market Overview

---

The biomarkers market size was valued at USD 45.11 billion in 2021 and is projected to reach USD 86.41 billion by 2027, exhibiting a CAGR of 11.44% during the forecast period.

The growth of the market is primarily driven by the increasing adoption of biomarkers in personalized medicine and the rising focus on digital biomarkers. Biomarkers have become valuable tools for predicting prognosis and therapy response in cancer patients, leading to a better understanding of treatment mechanisms and resistance. They are also gaining prominence in the field of autoimmune diseases, with researchers actively working on discovering new biomarkers such as autoantibodies.

Vendors in the market are focusing on increasing biomarker discoveries and developing biomarker-based diagnostics to meet the high demand in personalized medicine and drug discovery. The emphasis is on tailoring treatments to individual patients, thereby increasing the demand for biomarker research.

The increased adoption of biomarkers in personalized medicine is a significant driver of the global market growth. As healthcare settings increasingly embrace personalized/precision medicine, vendors are conducting more studies to identify biomarkers that can provide healthcare solutions tailored to individual patients’ needs.

Additionally, the growing focus on digital biomarkers is expected to drive market growth. Digital biomarkers are currently being tested for their feasibility and reliability in Parkinson’s and Alzheimer’s disease, as well as in clinical outcome assessments.

Moreover, the discovery of epigenetic biomarkers in oncology is contributing to the growth of the biomarker technologies market. Emerging companies are intensifying their research and development efforts to identify a broader range of epigenetic biomarkers for diagnosing various types of cancers.

Furthermore, technological advancements in genomic biomarker discovery are positively impacting the biomarker diagnostics industry. Portable biosensors, for instance, have recently been developed, enabling rapid, accurate, and on-site detection of biomarkers. This advancement plays a crucial role in preventing the spread of diseases by allowing for better control and management of potential sources.

Overall, the biomarkers market is witnessing significant growth due to the increased adoption of personalized medicine, the focus on digital biomarkers, the discovery of epigenetic biomarkers, and advancements in genomic biomarker technologies.

---

Market Segmentation

---

The market is segmented based on various factors, including indication, application, type, and geography.

Segmentation by Indication
Oncology
Cardiology
Neurology
Immunology
Others

Segmentation by Application
Diagnostics
Drug Discovery & Development
Personalized Medicine (PM)
Others

Segmentation by Type
Diagnostic Biomarker
Monitoring Biomarker
Prognostic Biomarker
Susceptibility Biomarker
Other Biomarker

Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey

In 2021, the oncology segment represented over 30% of the global market share, highlighting the extensive use of biomarkers in cancer research and medicine. Physicians are increasingly relying on cancer biomarkers to gather more precise information about a patient’s tumor and predict the most effective treatment tailored to their unique cancer condition.

In terms of application, the diagnostics segment will continue to lead the biomarkers industry. Biomarkers play a crucial role in the rational development of medical diagnostics and therapeutics. The emergence of complex composite and digital biomarkers derived from sensors and mobile technologies, as well as biomarker-driven predictive toxicology and systems pharmacology, is reshaping the landscape of diagnostic and therapeutic technologies in the genomic biomarkers market.

Among all market segments, the diagnostic biomarkers market is expected to witness the highest growth. Many diseases have distinct subtypes with varying prognoses and responses to specific treatments. Diagnostic biomarkers that identify these disease subtypes often play critical roles when the results of diagnostic classification are used as prognostic biomarkers and predictive biomarkers.

North America holds the largest share in the biomarkers market. The concept of personalized medicine is gaining significant attention in North America, leading to a rise in projects and funding. In recent years, the FDA has expanded its approvals for new gene therapies in the treatment of rare diseases and has qualified the first digital technology platform through its pre-certification program. In the United States, there are also future opportunities to adopt advanced technologies such as digital biomarkers, enabling more streamlined disease management.

The APAC region has exhibited the highest growth rate in the biomarkers industry. High-income countries like China, Japan, and Australia have been at the forefront of biomarker adoption in the APAC region. In India and South Korea, the biomarker market is driven by increasing medical costs, the prevalence of chronic illnesses, and an aging population. Notably, South Korea is predicted to experience robust growth in the precision medicine market over the next decade. The country has made significant investments in personalized medicine and plans to leverage big data to foster the growth of biotech start-up companies in the coming years.

---

Competitive Landscape

---

The key players in the market include Abbott company, BioMerieux, Biohit OYJ, CENTOGENE, Creative Diagnostics, Hoffmann-La Roche company, Fujirebio, General Electric (GE) company, and TAmiRNA.

Vendors are also required to develop new product launches and provide sufficient clinical trial data to obtain regulatory approval more easily.

Multiple companies engaging in partnerships and investments in biomarkers research and development will facilitate innovation of new drugs and alleviate the economic burden.

Vendors should strategically focus on inorganic growth through mergers and acquisitions, enhance collaborations with various research organizations and academic institutions, and initiate socioeconomic initiatives to raise awareness.

Key companies profiled in this report include Abbott company, BioMerieux, Biohit OYJ, CENTOGENE, Creative Diagnostics, F. Hoffmann-La Roche company, Fujirebio, General Electric (GE) company, TAmiRNA, Accure Therapeutics, Agilent, Almac Group, Applied Research Using OMIC Sciences (AROMICS), Bio-Rad Laboratories, BioVision, Caris Life Sciences, Denovo Biopharma, Dreamgenics, Eisai, Epigenomics, Immunovia, Insilico Medicine, Lexogen, Monument Tx, Oryzon Genomics, Plexision, Rules-Based Medicine, Siemens Healthineers, Second Genome Therapeutics, Thermo Fisher Scientific, Ymir Genomics.

---

Key Questions Answered

---

What is the current market size of the global biomarkers industry?

The biomarkers industry achieved a valuation of USD 45.11 billion in 2021 and is projected to reach USD 86.41 billion by 2027, with a compound annual growth rate (CAGR) of 11.44% during the forecast period.

Who are the key players in the biomarkers industry?

The prominent players in the biomarkers industry include Abbott company, BioMerieux, Biohit OYJ, CENTOGENE, Creative Diagnostics, F. Hoffmann-La Roche company, Fujirebio, General Electric (GE) company, and TAmiRNA.

What are the main factors driving the growth of the biomarkers industry?

The significant drivers of the biomarkers industry include the increasing adoption of precision medicine, the growing popularity of digital biomarkers, the rise in the number of pipeline biomarkers, and the expanding utilization in disease diagnostics.

Which region holds the largest market share in the biomarkers industry?

North America holds the highest market share in the biomarkers industry.

Which application segment is leading in the biomarkers industry?

In terms of application, the diagnostics segment is leading the biomarkers industry.